Compare Sanofi India with Jubilant Pharmova - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs JUBILANT PHARMOVA - Comparison Results

SANOFI INDIA     Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA JUBILANT PHARMOVA SANOFI INDIA/
JUBILANT PHARMOVA
 
P/E (TTM) x 39.5 14.6 270.6% View Chart
P/BV x 8.0 2.7 295.0% View Chart
Dividend Yield % 1.1 0.5 198.3%  

Financials

 SANOFI INDIA   JUBILANT PHARMOVA
EQUITY SHARE DATA
    SANOFI INDIA
Dec-18
JUBILANT PHARMOVA
Mar-19
SANOFI INDIA/
JUBILANT PHARMOVA
5-Yr Chart
Click to enlarge
High Rs6,840898 761.7%   
Low Rs4,630618 749.8%   
Sales per share (Unadj.) Rs1,203.1572.0 210.3%  
Earnings per share (Unadj.) Rs165.336.2 456.2%  
Cash flow per share (Unadj.) Rs209.959.5 352.6%  
Dividends per share (Unadj.) Rs84.004.50 1,866.7%  
Dividend yield (eoy) %1.50.6 246.6%  
Book value per share (Unadj.) Rs963.6301.9 319.2%  
Shares outstanding (eoy) m23.03159.28 14.5%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x4.81.3 359.8%   
Avg P/E ratio x34.720.9 165.9%  
P/CF ratio (eoy) x27.312.7 214.6%  
Price / Book Value ratio x6.02.5 237.1%  
Dividend payout %50.812.4 409.2%   
Avg Mkt Cap Rs m132,078120,694 109.4%   
No. of employees `0003.32.4 138.1%   
Total wages/salary Rs m4,06819,260 21.1%   
Avg. sales/employee Rs Th8,393.838,120.6 22.0%   
Avg. wages/employee Rs Th1,232.48,058.4 15.3%   
Avg. net profit/employee Rs Th1,153.02,414.3 47.8%   
INCOME DATA
Net Sales Rs m27,70891,108 30.4%  
Other income Rs m897357 251.0%   
Total revenues Rs m28,60591,466 31.3%   
Gross profit Rs m6,23517,390 35.9%  
Depreciation Rs m1,0273,709 27.7%   
Interest Rs m72,198 0.3%   
Profit before tax Rs m6,09811,840 51.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-2,802 0.0%   
Tax Rs m2,2923,268 70.1%   
Profit after tax Rs m3,8065,770 66.0%  
Gross profit margin %22.519.1 117.9%  
Effective tax rate %37.627.6 136.2%   
Net profit margin %13.76.3 216.9%  
BALANCE SHEET DATA
Current assets Rs m15,92245,848 34.7%   
Current liabilities Rs m6,23520,897 29.8%   
Net working cap to sales %35.027.4 127.7%  
Current ratio x2.62.2 116.4%  
Inventory Days Days6457 112.1%  
Debtors Days Days2151 41.0%  
Net fixed assets Rs m7,53965,498 11.5%   
Share capital Rs m230159 144.4%   
"Free" reserves Rs m21,96247,930 45.8%   
Net worth Rs m22,19248,089 46.1%   
Long term debt Rs m042,429 0.0%   
Total assets Rs m29,839114,685 26.0%  
Interest coverage x872.16.4 13,655.7%   
Debt to equity ratio x00.9 0.0%  
Sales to assets ratio x0.90.8 116.9%   
Return on assets %12.86.9 183.9%  
Return on equity %17.212.0 142.9%  
Return on capital %27.512.4 221.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m7,58712,422 61.1%   
Fx outflow Rs m7,14517,227 41.5%   
Net fx Rs m442-4,805 -9.2%   
CASH FLOW
From Operations Rs m3,73911,215 33.3%  
From Investments Rs m-731-10,118 7.2%  
From Financial Activity Rs m-1,9726,574 -30.0%  
Net Cashflow Rs m1,0367,612 13.6%  

Share Holding

Indian Promoters % 0.0 45.6 -  
Foreign collaborators % 60.4 3.5 1,725.7%  
Indian inst/Mut Fund % 14.4 8.7 165.5%  
FIIs % 14.6 21.2 68.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 21.1 49.8%  
Shareholders   15,184 23,815 63.8%  
Pledged promoter(s) holding % 0.0 15.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   NOVARTIS  TORRENT PHARMA  DISHMAN PHARMA  WYETH  ASTRAZENECA PHARMA  

Compare SANOFI INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Go Airlines Files DRHP, Happiest Minds Q4 Performance, and Buzzing Stocks Today(Pre-Open)

Indian share markets ended on a flat note on Friday. Benchmark indices fluctuated between gains and losses as rising inflation in the US.

Related Views on News

SANOFI INDIA Announces Quarterly Results (2QFY21); Net Profit Up 5.0% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 5.0% YoY). Sales on the other hand came in at Rs 7 bn (down 11.9% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY21); Net Profit Up 39.9% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 39.9% YoY). Sales on the other hand came in at Rs 7 bn (down 5.0% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY20); Net Profit Up 358.8% (Quarterly Result Update)

Jun 1, 2020 | Updated on Jun 1, 2020

For the quarter ended March 2020, JUBILANT LIFE SCIENCES has posted a net profit of Rs 3 bn (up 358.8% YoY). Sales on the other hand came in at Rs 24 bn (up 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY20); Net Profit Down 8.1% (Quarterly Result Update)

May 21, 2020 | Updated on May 21, 2020

For the quarter ended March 2020, SANOFI INDIA has posted a net profit of Rs 854 m (down 8.1% YoY). Sales on the other hand came in at Rs 8 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (3QFY20); Net Profit Down 24.0% (Quarterly Result Update)

Feb 1, 2020 | Updated on Feb 1, 2020

For the quarter ended December 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 24.0% YoY). Sales on the other hand came in at Rs 23 bn (down 2.6% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

Is Intraday Trading For You?(Fast Profits Daily)

May 13, 2021

Do you think you have what it takes to be an intraday trader? Find out in this video.

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

The Key to Profit from India's EV Revolution(Profit Hunter)

May 7, 2021

Stocks you must consider investing in before buying your first electric vehicle.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


May 14, 2021 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 8-QTR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS